Pharvaris (PHVS) director David Meeker reports stock, options and RSUs
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Pharvaris N.V. director David P. Meeker reports his current equity holdings, including common shares, stock options and restricted stock units. He holds 65,167 shares of Common Stock directly, as well as multiple stock option awards to buy additional shares at exercise prices ranging from $7.89 to $28.00 per share, with expirations between 2031 and 2036. The filing also notes outstanding restricted stock units, including 5,500 RSUs from an award granted on March 3, 2026 that will fully vest on March 3, 2027, settling in common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Meeker David P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,500 shares (Direct);
Common Stock — 65,167 shares (Direct)
Footnotes (1)
- Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027. 100% of the option vest on the 12-month anniversary. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
FAQ
What does the Pharvaris (PHVS) Form 3 filing by David P. Meeker show?
The Form 3 shows that director David P. Meeker reports his existing equity holdings in Pharvaris N.V., including common stock, stock options and restricted stock units. It is an initial statement of beneficial ownership, not a report of new share purchases or sales.
What stock options does David P. Meeker report in the Pharvaris (PHVS) Form 3?
Meeker reports several Stock Option (Right to Buy) awards over Pharvaris common stock, with exercise prices such as $7.89, $8.05, $16.05, $18.14, $22.31 and $28.00, and expiration dates ranging from 2031 through 2036, all held directly.
What restricted stock units (RSUs) does David P. Meeker hold in Pharvaris (PHVS)?
The filing notes outstanding restricted stock units granted under Pharvaris’s equity plan, which settle in common stock. This includes 5,500 RSUs from an award granted on March 3, 2026, scheduled to vest 100% on March 3, 2027, as described in the footnotes.
What are the key expiration dates for David P. Meeker’s Pharvaris (PHVS) stock options?
Meeker’s reported stock options over Pharvaris common stock have staggered expiration dates, including January 1, 2031, April 1, 2032, April 6, 2033, April 11, 2034, March 12, 2035 and March 3, 2036, reflecting long-dated equity incentives.